CCR 20th anniversary commentary: Triple-negative breast cancer in 2015 - Still in the ballpark

Clinical Cancer Research

Volumn 21, Issue 17, 2015, Pages 3813-3814

  Narod, Steven A ^a   Dent, Rebecca A ^b   Foulkes, William D ^c  

^a UNIVERSITY OF TORONTO   (Canada)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC METAL COMPLEX; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; ESTROGEN RECEPTOR; OLAPARIB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROGESTERONE RECEPTOR;

BREAST CANCER; CANCER CLASSIFICATION; CANCER RESEARCH; CANCER THERAPY; GENE EXPRESSION; GENOMICS; HUMAN; METASTASIS; OVARIECTOMY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TRIPLE NEGATIVE BREAST CANCER; BREAST NEOPLASMS; FEMALE; METABOLISM; PATHOLOGY; TUMOR RECURRENCE;

BREAST NEOPLASMS; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 84942910054     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-3122     Document Type: Review

References (14)

1. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature 2000; 406: 747-52.
2. Blows FM, Driver KE, Schmidt MK, Broeks A, Van Leeuwen FE, Wesseling J, et al. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10, 159 cases from 12studies. PLoS Med 2010; 7: e1000279.
3. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. Identification of human triple-negative breast cancer subtypes and pre-clinical models for selection of targeted therapies. J Clin Invest 2011; 121: 2750-67.
4. + lymphocyte infiltration isanindependent favorable prognostic indicator in basal-like breast cancer. Breast Cancer Res 2012; 14: R48.
5. Chawla A, Philips AV, Alatrash G, Mittendorf E. Immune checkpoints: a therapeutic target in triple negative breast cancer. Oncoimmunology 2014; 3: e28325.
6. Collins FS, Varmus H. Anew initiative on precision medicine. N Engl J Med 2015; 372: 793-5.
7. Wang Y, Waters J, Leung ML, Unruh A, Roh W, Shi X, et al. Clonal evolution in breast cancer revealed by single nucleus genome sequencing. Nature 2014; 512: 155-60.
8. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010; 376: 235-44.
9. Cameron D, Brown J, Dent R, Jackisch C, Mackey J, Pivot X, et al. Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial. Lancet Oncol 2013; 14: 933-42.
10. Silver DP, Richardson AL, Eklund AC, Wang ZC, Szallasi Z, Li Q, et al. Efficacy of neoadjuvant cisplatin in triple-negative breast cancer. J Clin Oncol 2010; 28: 1145-53.
11. Byrski T, Huzarski T, Dent R, Marczyk E, Jasiowka M, Gronwald J, et al. Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat 2014; 147: 401-5.
12. Couch FJ, Hart SN, Sharma P, Toland AE, Wang X, Miron P, et al. Inherited mutations in 17 breast cancer susceptibility genes among a large triplenegative breast cancer cohort unselected for family history of breast cancer. J Clin Oncol 2015; 33: 304-11.
13. Villarreal-Garza C, Weitzel JN, Llacuachaqui M, Sifuentes E, Magallanes-Hoyos MC, Gallardo L, et al. The prevalence of BRCA1 and BRCA2 mutations among young Mexican women with triple-negative breast cancer. Breast Cancer Res Treat 2015; 150: 389-94.
14. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007; 13: 4429-34.